coding.bio

The core of coding.bio's business is its proprietary platform that combines a high-throughput wet lab with a machine learning engine. This dual platform approach enables the company to screen millions of potential therapeutic candidates directly in living cells. By generating vast amounts of data on how modular proteins induce an immune response, the company moves beyond analyzing simple protein binding to identify optimal therapy designs. The machine learning component analyzes protein structures to discern patterns that influence therapeutic quality and then iteratively refines designs to maximize performance. This integrated system is designed to significantly shorten the development timeline for new immunotherapies, allowing partners to advance to clinical trials more rapidly.

The company's business model appears to be centered on partnerships with pharmaceutical and biotechnology companies, helping them build and deliver modular therapies such as Chimeric Antigen Receptors (CARs) and Bispecific T-cell Engagers (BiTEs). By leveraging its AI-driven discovery platform, coding.bio offers a more efficient path to creating effective therapeutics. Since its inception, the company has secured approximately $3.45 million in seed funding over two rounds in 2022, with investors including BoxOne Ventures and The Venture Collective, to advance its platform and operations.